Capital Impact Advisors LLC continued to hold its stake in shares of Mednax, Inc (NYSE:MD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,993 shares of the company’s stock at the end of the second quarter. Capital Impact Advisors LLC’s holdings in Mednax were worth $1,509,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of MD. GW Henssler & Associates Ltd. boosted its position in Mednax by 12.7% in the first quarter. GW Henssler & Associates Ltd. now owns 152,837 shares of the company’s stock worth $10,604,000 after buying an additional 17,183 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock worth $158,000 after buying an additional 102 shares during the last quarter. Retirement Systems of Alabama boosted its position in Mednax by 0.9% in the first quarter. Retirement Systems of Alabama now owns 175,089 shares of the company’s stock worth $12,148,000 after buying an additional 1,477 shares during the last quarter. Hermes Investment Management Ltd. boosted its position in Mednax by 4.7% in the first quarter. Hermes Investment Management Ltd. now owns 807,096 shares of the company’s stock worth $55,996,000 after buying an additional 36,545 shares during the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in shares of Mednax by 5.2% in the first quarter. State of Alaska Department of Revenue now owns 4,136 shares of the company’s stock worth $286,000 after buying an additional 204 shares during the last quarter.
Shares of Mednax, Inc (MD) traded down 15.51% on Friday, reaching $47.73. 3,638,964 shares of the company were exchanged. The company has a market capitalization of $4.41 billion, a price-to-earnings ratio of 14.25 and a beta of 0.44. The company’s 50-day moving average is $57.87 and its 200-day moving average is $63.24. Mednax, Inc has a 52 week low of $46.70 and a 52 week high of $72.13.
Mednax (NYSE:MD) last posted its earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 12.81% and a net margin of 9.54%. The firm had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the previous year, the business earned $1.03 earnings per share. The firm’s revenue was up 9.2% compared to the same quarter last year. On average, equities analysts expect that Mednax, Inc will post $3.58 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/07/29/capital-impact-advisors-llc-continues-to-hold-stake-in-mednax-inc-md-updated.html.
MD has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Thursday, April 27th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research note on Thursday, May 4th. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. TheStreet cut shares of Mednax from a “b-” rating to a “c+” rating in a research note on Tuesday, May 16th. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $55.00 to $68.00 in a report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company’s stock. Mednax presently has a consensus rating of “Hold” and a consensus target price of $65.89.
In other news, CFO Vivian Lopez-Blanco sold 7,778 shares of the company’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $55.82, for a total value of $434,167.96. Following the sale, the chief financial officer now directly owns 51,319 shares in the company, valued at $2,864,626.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the transaction, the director now owns 18,072 shares in the company, valued at $1,040,405.04. The disclosure for this sale can be found here. In the last three months, insiders sold 33,074 shares of company stock worth $1,830,508. Corporate insiders own 2.40% of the company’s stock.
About Mednax
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.
